Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

The Key to Stopping Sarcomas’ Spread

By Drug Discovery Trends Editor | May 13, 2015

Poul Sorensen. Source: BC Cancer FoundationWhen sarcomas become large enough and outgrow their blood supply, they become vulnerable to hypoxia — a lack of oxygen. That adaptation not only enables them to survive the stress of low oxygen — it also enables them to withstand cancer drugs.

Poul Sorensen, a Professor in the Department of Pathology & Laboratory Medicine and Johal Chair in Childhood Cancer Research, has found a previously unrecognized pathway that allows those sarcomas to withstand the stress of hypoxia or cancer drugs.

His research, published May 11 in Cancer Cell, describes how a protein called YB-1, which is highly expressed across virtually all human sarcoma subtypes, can directly stimulate the production of another protein, HIF1a, which makes tumor cells stress-resistant and thus more invasive.

Sarcomas are tumors of the connective tissues, including bones and muscles. They are more common in children and can be extremely difficult to treat because they have a high tendency to metastasize, or spread. There has been little progress in treating the condition for the past two decades, in part because its metastatic mechanism has eluded scientists.

“This process appears to be specific for tumor cells, which could have profound implications for targeting the YB-1-HIF1α pathway therapeutically,” said Dr. Sorensen, a Distinguished Scientist at the BC Cancer Agency, who conducted the research with Amal El-Naggar, a post-doctoral fellow.

By blocking the production of HIF1a through the YB-1 pathway, Dr. Sorensen and Dr. El-Naggar found that local tumors more susceptible to low oxygen conditions, dramatically inhibiting the spread of childhood sarcoma cells to the lungs. With this knowledge, researchers are now trying to find a drug that would target this pathway.

There may also be therapeutic applications for other cancers. The data suggests that this pathway is also active in adult epithelial cancers such as breast cancer.

There are 12 cases of sarcoma per year in B.C., and approximately 30-40 per cent of patients die of their disease, particularly in high-risk disease.

Source: UBC


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE